AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Chronic nonalcoholic steatohepatitis (NASH) is a metabolic disorder that often leads to liver fibrosis, a condition with limited therapy options. Adiponectin is an adipocytokine that regulates glucose and lipid metabolism via binding to its receptors AdipoR1 and AdipoR2, and AdipoRs signaling is reported to enhance fatty acid oxidation and glucose uptake. Here, we synthesize and report an adiponectin-based agonist JT003, which potently improves insulin resistance in high fat diet induced NASH mice and suppresses hepatic stellate cells (HSCs) activation in CCl 4 induced liver fibrosis. Mechanistic studies indicate that JT003 simultaneously stimulates AdipoR1- and AdipoR2- mediated signaling pathways as well as the PI3K-Akt pathway. Moreover, JT003 treatment significantly improves ER-mitochondrial axis function, which contributes to the reduced HSCs activation. Thus, the AdipoR1/AdipoR2 dual agonist improves both NASH and fibrosis in mice models, which provides the pharmacological and biological foundation for developing AdipoRs-based therapeutic agents on liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1557 · Cited by 1,396
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Adiponectin and AdipoR1 Regulate PGC-1α and Mitochondria by Ca2+ and AMPK/SIRT1
Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., et al. (2010) · Nature · doi:10.1038/nature08991 · Cited by 971
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757
Research works printed but not linked: 38
- Wesolowski, S. R., Kasmi, K. C., Jonscher, K. R. & Friedman, J. E. Developmental origins of NAFLD: a womb with a clue. Nat. Rev. Gastroenterol. Hepatol. 14, 81–96 (2017). · DOI · Paper page
- Musso, G., Cassader, M. & Gambino, R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 15, 249–274 (2016). · DOI · Paper page
- Friedman, S. L. Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH. Nat. Rev. Gastroenterol. Hepatol. 10, 71–72 (2013). · DOI
- Nassir, F. & Ibdah, J. A. Role of mitochondria in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15, 8713–8742 (2014). · DOI · Paper page
- Baiceanu, A., Mesdom, P., Lagouge, M. & Foufelle, F. Endoplasmic reticulum proteostasis in hepatic steatosis. Nat. Rev. Endocrinol. 12, 710–722 (2016). · DOI · Paper page
- Filozof, C., Goldstein, B. J., Williams, R. N. & Sanyal, A. Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 75, 1373–1392 (2015). · DOI · Paper page
- Ratziu, V. et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55, 419–428 (2012). · DOI · Paper page
- Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. & Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746–26749 (1995). · DOI · Paper page
- Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98, 2005–2010 (2001). · doi:10.1073/pnas.98.4.2005 · Paper page
- Tanabe, H. et al. Crystal structures of the human adiponectin receptors. Nature 520, 312–316 (2015). · DOI · Paper page
- Vasiliauskaité-Brooks, I. et al. Structural insights into adiponectin receptors suggest ceramidase activity. Nature 544, 120–123 (2017). · DOI · Paper page
- Tomita, K. et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 48, 458–473 (2008). · DOI · Paper page
- Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. 19, 121–135 (2017). · DOI · Paper page
- Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720–733 (2015). · DOI · Paper page
- Chou, I. P., Lin, Y. Y., Ding, S. T. & Chen, C. Y. Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitate-treated HepG2 cells through the PI3 K/AKT pathway. Eur. J. Nutr. 53, 907–917 (2014). · DOI
- Matsuda, S., Kobayashi, M. & Kitagishi, Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol. 2013, 472432 (2013). · DOI · Paper page
- Wang, H. et al. Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. Sci. Rep. 6, 19445 (2016). · DOI
- Ma, L. et al. A potent peptide as adiponectin receptor 1 agonist to against fibrosis. J. Enzym. Inhib. Med. Chem. 32, 624–631 (2017). · DOI
- Min, X. et al. Crystal structure of a single-chain trimer of human adiponectin globular domain. FEBS Lett. 586, 912–917 (2012). · DOI
- Otvos, L. et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 11, 90 https://doi.org/10.1186/1472-6750-11-90 (2011). · DOI · Paper page
- Kumar, P. et al. Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS ONE 9, e110405 https://doi.org/10.1371/journal.pone.0110405 (2014). · DOI · Paper page
- Titchenell, P. M., Lazar, M. A. & Birnbaum, M. J. Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol. Metab. 28, 497–505 (2017). · DOI · Paper page
- Rines, A. K., Sharabi, K., Tavares, C. D. J. & Puigserver, P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat. Rev. Drug Discov. 15, 786–804 (2016). · DOI · Paper page
- Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159–169 (2012). · DOI · Paper page
- Filadi, R., Theurey, P. & Pizzo, P. The endoplasmic reticulum-mitochondria coupling in health and disease: molecules, functions and significance. Cell Calcium 62, 1–15 (2017). · DOI · Paper page
- Dasarathy, S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology 60, 22–25 (2014). · DOI
- Handa, P. et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 60, 133–145 (2014). · DOI · Paper page
- Verfaillie, T. et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 19, 1880–1891 (2012). · DOI · Paper page
- Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411 (2017). · DOI · Paper page
- Yamauchi, T. & Kadowaki, T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 17, 185–196 (2013). · DOI · Paper page
- Kersten, S. Integrated physiology and systems biology of PPARalpha. Mol. Metab. 3, 354–371 (2014). · DOI · Paper page
- Saxena, N. K. & Anania, F. A. Adipocytokines and hepatic fibrosis. Trends Endocrinol. Metab. 26, 153–161 (2015). · DOI · Paper page
- Kamada, Y. et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125, 1796–1807 (2003). · DOI · Paper page
- Zhao, Q. et al. Rapeseed protein-derived antioxidant peptide RAP ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Mol. Pharm. 16, 371–381 (2018). · DOI
- Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K. & Ueno, H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 128, 138–146 (2005). · DOI · Paper page
- Leiva, O. et al. The role of the extracellular matrix in primary myelofibrosis. Blood Cancer J. 7, e525 (2017). · DOI
- Xie, J. et al. Antimicrobial activities and action mechanism studies of transportan 10 and its analogues against multidrug-resistant bacteria. J. Pept. Sci. 21, 599–607 (2015). · doi:10.1002/psc.2781
- Xie, J. et al. Novel antimicrobial peptide CPF-C1 analogs with superior stabilities and activities against multidrug-resistant bacteria. Chem. Biol. Drug Des. 90, 690–702 (2017). · DOI
Cited by
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Targeting PI3K/AKT signaling pathway in obesity
Savova, M. S., Mihaylova, L. V., Tews, D., Wabitsch, M., & Georgiev, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114244 · Cited by 277
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“…ACC inhibitors (alone or in combination with DGAT inhibitors) [105,142,143], FASN inhibitors [144], and adiponectin receptor 1/2 agonists have shown preclinical and/or clinical promises in reducing fibrosis and MASH progression, raising high expectations for their future clinical efficacy [145].”
Lee, J., Byun, J., Shim, G., & Oh, Y.-K. (2022) · Nature Communications · doi:10.1038/s41467-022-29186-8 · Cited by 79
Metadata
- Authors
- Xu, H., Zhao, Q., Song, N., Yan, Z., Lin, R., Wu, S., Jiang, L., Hong, S., Xie, J., Zhou, H., Wang, R., & Jiang, X.
- Venue
- Nature Communications
- Published
- 2020-11-16
- Volume
- 11
- Issue
- 1
- Pages
- 5807-5807
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3105465401
- Cited by
- 148
- References
- 15
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-03-26)
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. https://app.cochat.ai/papers/10.1038/s41467-020-19668-y
- The paper
- Xu, H., Zhao, Q., Song, N., Yan, Z., Lin, R., Wu, S., Jiang, L., Hong, S., Xie, J., Zhou, H., Wang, R., & Jiang, X. (2020). AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. Nature Communications. https://doi.org/10.1038/s41467-020-19668-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.